Lipophilicity, a significant physicochemical parameter of bioactive molecules, along with absorption, distribution, metabolism, excretion parameters and toxicity risk, was investigated for 32 thiazolo[3,2-b][1,2,4]triazole and imidazo[2,1-b][1,3,4]thiadiazole derivatives with anti-inflammatory potential. The experimental lipophilicity study was carried out by reversed-phase thin-layer chromatography in a binary isopropanol-water mobile phase, and the obtained results were compared with the theoretical lipophilicity parameters estimated by various computational methods. Strong correlations were found between the experimental retention factors and calculated partition coefficients. A modified Petra/Osiris/Molinspiration analysis was performed on the previously synthesized compounds, using SwissADME, Osiris and Molinspiration web tools. The predicted in silico parameters highlighted the most promising compounds as potential drug candidates. The compounds showed good gastrointestinal absorption, moderate activity according to the bioactivity score (values situated between −1.25 and −0.06), and a safe toxicity profile. The results obtained in this study will contribute to lipophilicity studies and other future studies focused on modulating new drug candidates starting from thiazolo[3,2-b][1,2,4]triazole and imidazo[2,1-b][1,3,4]thiadiazole derivatives, which are important heterocycles in medicinal chemistry.
Background. Pulmonary superinfections increase the mortality risk among COVID-19 patients, highlighting the need for enhanced understanding to enable early and accurate diagnosis. Methods. We present the case of a patient, a 76-year-old man, hospitalized for a severe form of COVID-19, with a ground-glass pneumonia, involving 40–45% of lung surfaces. Results. In evolution, the clinical condition worsened, presenting leukocytosis with neutrophilia, imaging towards resorption, and computer tomography images showing the appearance of pulmonary condensations in the right lower lobe, the posterior portion of the left lower lobe and pleural collections. Carbapenemase-producing Klebsiella pneumoniae was isolated from the tracheal aspirate, and the real-time polymerase chain reaction test was positive for Klebsiella pneumoniae and Legionella pneumophila. The investigations that were carried out allowed us to establish the coinfections as a probable case of Legionnaire’s disease and a ventilator-associated pneumonia with Klebsiella pneumoniae. Conclusions. The case analysis revealed that rare pneumonias may remain undiagnosed, and coinfections may be conditioned by pathophysiological factors or components of COVID-19 critical form treatment. Enhanced understanding of these aspects in clinical practice may contribute to reducing mortality risk in COVID-19 patients.
The anti-COVID-19 vaccines, developed for use during the pandemic period, must be evaluated for effectiveness in order to coordinate the vaccination program. Therefore, this study aimed to measure the anti-COVID-19 vaccine effectiveness (VE) and duration of protection against symptomatic forms of infection among healthcare personnel who were professionally exposed to the SARS-CoV-2 virus. A prospective cohort study, which was conducted in a university hospital between January 2021 and April 2022, compared immunologically naïve and previously infected personnel who were vaccinated, revaccinated, or unvaccinated. The VE was measured based on survival rates constructed with the actuarial method, using 30 day intervals. Among the 783 subjects that were included in the study, those that were vaccinated showed a decrease in VE from 90.98% (95% confidence intervals (CI): 74.87–96.77) in the first 30 days to 69.95% (95% CI: 40.29–84.87) at 60 days after vaccination. The VE for revaccinated personnel was 93.27% (95% CI: 77.53–97.99) at 60 days and 86.54% (95% CI: 75.59–92.58) at 90 days after revaccination. For previously infected personnel, protection against reinfection was 94.03% (95% CI: 79.41–98.27) at 420 days and 82.08% (95% CI: 53.93–93.03) at 450 days after revaccination. The highest VE for preventing the symptomatic forms of COVID-19 was observed in the revaccinated, but only for a 3-month duration. Better protection against reinfection was provided by revaccination after passing through infection.
Purpose: This scoping review aimed to map the available evidence on the safety and efficacy of anti-inflammatory dietary supplements used during pregnancy, assessing maternal and fetal outcomes. Methods: A systematic literature search was conducted in PubMed, Scopus, and Web of Science (January 2016–June 2026), following PRISMA-ScR guidelines. The protocol was prospectively registered on the Open Science Framework (10.17605/osf.io/4kmv9). Eligible studies included human clinical trials and observational studies evaluating anti-inflammatory dietary supplements in pregnant women. Results: Eighty unique studies (96 publications) from 28 countries were included, of which 63 (78.8%) were randomized clinical trials. Thirteen supplement categories were identified. Vitamin D (n = 23) and omega-3 fatty acids (n = 17) accounted for nearly half of all studies; probiotics (n = 11) formed the third-largest category. For these three supplements, most studies reported changes in inflammatory and glycemic markers, primarily in gestational diabetes mellitus and high-risk populations, but adverse events were collected in a minority of studies, so tolerability is documented rather than established. Evidence for zinc, magnesium, and alpha-lipoic acid was limited. Curcumin, chlorella, vitamin E, epigallocatechin-3-gallate (EGCG), resveratrol, and ginger were each supported by only one or two studies. Supplementation was initiated in the first trimester in 19 studies (23.8%), and neonatal safety outcomes were reported infrequently. Conclusions: Evidence on anti-inflammatory dietary supplements in pregnancy is concentrated in a few compounds, in a small number of countries, and in biochemical outcomes measured in selected populations. Tolerability was evaluated in only a small number of studies, which limits its use as an indicator of safety. The map highlights the scarcity of controlled studies with prespecified harm outcomes, of first-trimester initiation, and of infant follow-up beyond the first months of life.